08:35 AM EDT, 10/08/2025 (MT Newswires) -- Aardvark Therapeutics ( AARD ) said Wednesday it reached an alignment with the US Food and Drug Administration on expanding the patient population for its phase 3 trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome.

The expansion changes the minimum age of eligibility to take part in the trial to 10 years old from 13, the company said.